Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data

Table 6 Parameter values that have been specified via locally fitting the vascular tumour growth model to experimental data extracted from [62]

Cell line	Experimental group	λ ₁	c	d	β	p	K ₀	RMSE	FOO
		day⁻¹	mg/[day · mm^3p · kg]	day⁻¹ · mm⁻²	mm^3p	-	mm³	mm³
HCT116	Control	0.2362	0.4884	0.0017	-	-	194.5946	121.7580	7.35 · 10⁻¹
	Treatment	0.2362	0.3881	0.0017	1	5.7777	0.6	74.8503	6.61 · 10⁻²
	(15 mg/kg)	0.2362	0.3881	0.0017	1	5.7777	0.6	74.8503	6.61 · 10⁻²
HCP40	Control	0.1603	0.5036	0.0013	-	-	223.3251	47.8814	1.30 · 10⁻¹
	Treatment	0.1233	0.0186	0.0013	0.9062	12.4022	17.2066	9.3102	8.76 · 10⁻⁵
	(15 mg/kg)	0.1233	0.0186	0.0013	0.9062	12.4022	17.2066	9.3102	8.76 · 10⁻⁵
HT29	Control	0.2138	0.5061	0.0017	-	-	111.5735	58.1716	2.17 · 10⁻¹
	Treatment	0.2138	0.3783	0.0017	1	6.2774	0.6	129.8810	1.5 · 10⁻³
	(15 mg/kg)	0.2138	0.3783	0.0017	1	6.2774	0.6	129.8810	1.5 · 10⁻³
HP40	Control	0.2966	0.5056	0.0022	-	-	134.0895	100.5007	3.77 · 10⁻¹
	Treatment	0.2966	0.4356	0.0022	1	4.5576	23.0272	93.2413	1.33 · 10⁻¹
	(15 mg/kg)	0.2966	0.4356	0.0022	1	4.5576	23.0272	93.2413	1.33 · 10⁻¹

First-order optimality (FOO) is a measure of the closeness of the solution to the optimum

ISSN: 1745-6150